• 1. Methanocarba ring as a ribose modification in ligands of G protein-coupled purine and pyrimidine receptors: synthetic approaches
  Dilip K. Tosh,Kenneth A. Jacobson Med. Chem. Commun. 2013 4 619

Professional Introduction to 1,3-Dibutylxanthine (CAS No. 2850-36-4)

1,3-Dibutylxanthine, a compound with the chemical formula C₁₁H₁₆N₂O₂ and the CAS number 2850-36-4, is a derivative of xanthine that has garnered significant attention in the field of pharmacology and medicinal chemistry. This compound belongs to the xanthine family, which includes well-known molecules such as caffeine and theophylline, and has been studied for its potential therapeutic applications.

The structure of 1,3-Dibutylxanthine features two butyl groups attached at the 1 and 3 positions of the xanthine core. This structural modification imparts unique pharmacological properties that distinguish it from its parent compounds. The butyl groups enhance lipophilicity, potentially improving membrane permeability and thereby affecting cellular signaling pathways. This feature has made 1,3-Dibutylxanthine a subject of interest for developing novel therapeutic agents.

In recent years, research on 1,3-Dibutylxanthine has focused on its potential role in modulating adenosine receptors. Adenosine receptors are integral to various physiological processes, including neurotransmission, cardiovascular function, and inflammation. The compound has been shown to interact with both A1 and A2A adenosine receptors, although its selectivity profile is distinct from that of caffeine. Studies have suggested that 1,3-Dibutylxanthine may exhibit greater affinity for A2A receptors, which could make it a valuable tool in the treatment of conditions such as Parkinson's disease and ischemic stroke.

One of the most compelling aspects of 1,3-Dibutylxanthine is its potential as an anti-inflammatory agent. In preclinical studies, this compound has demonstrated ability to inhibit inflammatory pathways by modulating adenosine receptor activity. Specifically, it has been observed to reduce the production of pro-inflammatory cytokines such as TNF-α and IL-6. These findings are particularly intriguing given the high prevalence of chronic inflammatory diseases worldwide. The mechanism by which 1,3-Dibutylxanthine exerts its anti-inflammatory effects appears to involve both central nervous system modulation and peripheral immune responses.

The pharmacokinetic properties of 1,3-Dibutylxanthine have also been extensively studied. Unlike caffeine, which is rapidly metabolized by cytochrome P450 enzymes, 1,3-Dibutylxanthine exhibits a longer half-life. This extended duration of action suggests that it may be more effective in maintaining therapeutic levels over time. Additionally, its improved lipophilicity allows for better penetration across the blood-brain barrier, making it a promising candidate for central nervous system disorders.

Recent advancements in drug delivery systems have opened new avenues for utilizing 1,3-Dibutylxanthine. Nanoparticle-based formulations have been explored as a means to enhance bioavailability and targeted delivery. These formulations have shown promise in preclinical models for conditions such as neurodegenerative diseases and cancer. By optimizing particle size and surface chemistry, researchers aim to develop more effective therapeutic strategies using 1,3-Dibutylxanthine.

The toxicological profile of 1,3-Dibutylxanthine is another critical area of research. While initial studies suggest that it is well-tolerated at therapeutic doses, further investigation is needed to fully understand its safety profile. Long-term studies in animal models have not revealed any significant adverse effects at doses comparable to those used in human trials. However, comprehensive toxicological assessments are essential before clinical translation can proceed.

The development of novel pharmaceuticals often involves interdisciplinary collaboration between chemists, biologists, and clinicians. The case of 1,3-Dibutylxanthine exemplifies this collaborative approach. Medicinal chemists have synthesized various derivatives to optimize potency and selectivity, while biologists have investigated its mechanisms of action at the molecular level. Clinicians are evaluating its potential therapeutic benefits in human populations through clinical trials.

The future directions for research on 1,3-Dibutylxanthine are multifaceted. One area of focus is exploring its potential in combination therapies with other drugs that target adenosine receptors or inflammatory pathways. Such combinations may yield synergistic effects that enhance therapeutic outcomes. Additionally, computational modeling techniques are being employed to predict how modifications to the chemical structure might influence pharmacological properties.

In conclusion,1,3-Dibutylxanthine (CAS No. 2850-36-4) represents a promising compound with diverse applications in medicine. Its unique interaction with adenosine receptors and anti-inflammatory properties make it a valuable candidate for treating neurological disorders and chronic inflammatory conditions. Ongoing research continues to uncover new insights into its pharmacology and potential clinical uses, further solidifying its importance in modern drug discovery efforts.

• 28822-58-4(3-Isobutyl-1-methylxanthine)
• 31542-62-8(1,3-Dipropylxanthine)
• 41078-02-8(Enprofylline)
• 5967-84-0(Theophylline monohydrate)
• 317-34-0(Aminophylline)
• 1076-22-8(3-Methylxanthine)
• 109987-37-3(1H-Purine-2,6-dione-2-13C,3,7-dihydro-1-(methyl-d3)- (9CI))
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)